MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "MAO-B inhibitors"

  • 2024 International Congress

    A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease

    Y. Tan, Q. Wei, P. Xu, E. Tao, L. Wang, C. Cattaneo, H. Shang, S. Chen (Shanghai, China)

    Objective: To compare  efficacy and safety of safinamide and rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease (PD) by matching-adjusted indirect…
  • 2023 International Congress

    The monoamine oxidase-B inhibitor selegiline does not affect 18F-Florzolotau uptake in patients with progressive supranuclear palsy: a longitudinal case series

    XY. Li, TC. Yen, CT. Zuo, JW. Wang, JY. Lu, FT. Liu (Shanghai, China)

    Objective: In a longitudinal case series of patients with progressive supranuclear palsy (PSP), a chronic challenge with the irreversible MAO-B inhibitor selegiline was used to…
  • 2023 International Congress

    Estrogen and progesterone influence membrane functions and glucose transporter expression in synaptosomes of different age groups of naturally menopausal rats

    P. Kumar, N. Baquer (New Delhi, India)

    Objective: The objective of this study was to determine the effect of 17 β-estradiol (E2) and progesterone (P4) on the activities of Na+ K+ ATPase, monoamine…
  • 2023 International Congress

    Selegiline drives autophagic secretion of α-synuclein

    Y. Nakamura, S. Arawaka (Takatsuki, Japan)

    Objective: Our aim is to elucidate how selegiline drives extracellular secretion of α-synuclein (αS) and whether selegiline-induced αS secretion affects cell-to-cell transmission of αS. Background:…
  • 2023 International Congress

    Dyskinesia and adherence to safinamide and opicapone in fluctuating patients with Parkinson’s disease: observational retrospective study

    P. Lorenzo-Barreto, I. Pareés, P. Pérez-Torre, S. Fanjul, JL. López-Sendón, F. Pérez-Trapote, A. Sáez-Marín, E. Stiauren-Fernández, á. Patiño-Patón, JC. Martínez-Castrillo, A. Alonso-Cánovas (Madrid, Spain)

    Objective: To assess differences in the new onset or worsening of baseline dyskinesia after the introduction of safinamide (SA) or opicapone (OP) as add-on therapy…
  • 2023 International Congress

    Dopamine dysregulation syndrome in Parkinson’s disease controlled by safinamine

    SK. Song, JH. Kang (Jeju-Si, Republic of Korea)

    Objective: To describe a case of dopamine dysregulation syndrome managed by safinamide. Background: Dopamine dysregulation syndrome (DDS) is an uncommon non-motor symptom of Parkinson disease…
  • 2023 International Congress

    SAFE-DBS – A monocentric, randomised, blind evaluation of safinamide in the perioperative period in Parkinsonian patients with deep brain stimulation

    E. Gülke, M. Höfs, H. Pinnschmidt, A. Gulberti, C. Moll, U. Hidding, C. Buhmann, M. Heise, W. Hamel, M. Pötter-Nerger (Hamburg, Germany)

    Objective: This monocentric, randomised, blind study is designed to evaluate the effect of safinamide on motor and neuropsychiatric symptoms in the 3 month perioperative period…
  • 2023 International Congress

    The efficacy of dopamine agonists or monoamine oxidase type B inhibitors as monotherapy in patients with early Parkinson disease: A network meta-analysis

    CSC. Chuang (Changhua, Taiwan)

    Objective: This study aimed to investigate the effectiveness of dopamine agonists or monoamine oxidase type B inhibitors (MAOB-I) as monotherapy in patients with early Parkinson's…
  • 2022 International Congress

    SAFINAMIDE: REAL LIFE STUDY. EFFICACY IN SWITCH FROM RASAGILINA AND LOW-DOSE TREATMENT.

    MI. Morales-Casado, N. López-Ariztegui, DD. García-Meléndez, A. Diezma-Martín (Toledo, Spain)

    Objective: Evaluate the efficacy of safinamide in fluctuations in Parkinson's disease in real life. Analysis by subgroups: Switch rasagiline to safinamide and treatment with low…
  • 2022 International Congress

    Safinamide adherence: the experience of the movement disorder unit of Trieste.

    M. Catalan, M. Liccari, V. Tommasini, L. Antonutti, P. Manganotti (Trieste, Italy)

    Objective: Describe the clinical experience with Safinamide and assess the patients’ adherence to this treatment in the movement disorders centre of Trieste-Italy. Background: Safinamide (Xadago®)…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley